Advertisement
Pieter R. Stella, MD, Director, Cardiovascular Research, UniversityMedical Centre Utrecht, The Netherlands, and one of the CUSTOM clinical trialinvestigators, will present the data during a scientific symposium entitled,"The Drug Eluting Stent Summit, Part II," on Monday, October 13, 2008 at 2:54p.m., eastern time, at the Walter E. Washington Convention Center, Ballroom C,Level 3. The data presentation will be posted on the XTENT website athttp://www.xtentinc.com.
Advertisement
About XTENT
XTENT, Inc. is a medical device company focused on developing andcommercializing innovative customizable drug eluting stent (DES) systems forthe treatment of coronary artery disease (CAD). CAD is the most common form ofcardiovascular disease and the number one cause of death in the United Statesand Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable thetreatment of single lesions, long lesions and multiple lesions of varyinglengths and diameters, in one or more arteries with a single device.
Forward Looking Statements
This press release contains forward-looking statements within the meaningof the U.S. Private Securities Litigation Reform Act of 1995. Statements inthis press release regarding XTENT's business that are not historical factsmay be "forward-looking statements" that involve risks and uncertainties.Specifically, these statements include, but are not limited to thoseconcerning the timing of the release of its clinical trial data.Forward-looking statements are based on management's current, preliminaryexpectations, and are subject to risks and uncertainties that could causeactual results to differ from the results predicted and which are included inthe "Risk Factors" section of XTENT's quarterly report on Form 10-Q for thequarter ended June 30, 2008. This quarterly report was filed with the SEC onAugust 12, 2008, and is available on the company's investor relations websiteat http://www.xtentinc.com and on the SEC's website at http://www.sec.gov.Undue reliance should not be placed on forward-looking statements, which speakonly as of the date they are made. XTENT undertakes no obligation to updatepublicly any forward-looking statements to reflect new information, events orcircumstances after the date they were made, or to reflect the occurrence ofunanticipated events.
SOURCE XTENT, Inc.
